1. Scrip
  2. >>Business
  3. >>Manufacturing

Huge Samsung BioLogics IPO Reflects Rosy Manufacturing Outlook

 
• By Jung Won Shin

Samsung BioLogics has successful floated in one of South Korea’s largest ever IPOs and appears to be on track to becoming the top global contract manufacturer of biologics amid rising demand from cost-conscious global clients.

Samsung BioLogics’s “mega IPO” has drawn robust interest from institutional investors, reflecting the bright outlook for the contract manufacturing industry, the company’s timely investment to expand production capacity, and a rapidly progressing biosimilar pipeline at its subsidiary.

Samsung BioLogics raised KRW2.5tn ($2.18bn) from the Nov. 2-3 initial public offering, marking the second largest ever IPO in South...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

More from Business